12 May 2023
Ready for Market – How Do We Get ATMPs Over the Line in Europe?
Join us as a panel of experts discusses challenges in developing, launching and commercialising ATMPs in Europe. The panel of industry leaders will also share insights into which specific requirements have to be met to ensure the progress of European cell and gene therapy.
Latest Content
Don’t Miss Out on Our Next Webinar
Up Next: Predict & Prevent: Driving Efficiencies in CGT Manufacturing with Digitization and Partner-in-Plant Collaborations
Join the discussion employing digital solutions to monitor, track and mitigate challenges during advanced therapy manufacturing.
15 Jun 2023
Thursday, June 15, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]
Access Our Webinar Library
Our eBooks & Infographics
As manufacturing pipelines scale in line with increased demand for advanced therapies, there is further demand for digital solutions to support complex manufacturing process development.
This Case Study demonstrates how the Association for the Advancement of Blood & Biotherapeutics (AABB) evaluated the apparent challenges in identifying and retaining employees due to a shortage in the worldwide biotherapies workforce.
Gene-edited cell therapies represent a rapidly growing area for advanced therapeutic development, but manufacturing-related challenges remain to commercialize such complex therapies.
This Case Study demonstrates how the Excellos team successfully carried out process development of a scale up procedure from tissue culture stacks to a commercial bioreactor system.
This Case Study demonstrates how the use of Akadeum’s microbubble platform offers a simple and highly tunable isolation and activation workflow that generates T cells ready for suspended cell culture and downstream applications, such as genetic modification and expansion, and discusses the potential impact of the solution on cancer treatment.
What are the steps on the long and winding road from the lab bench to the clinic for a novel gene therapy?
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
In this infographic, we have detailed some key considerations when choosing your plasmids for CAR-T development.
As we celebrate 10 years of CAR-T, the Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for CAR-T development.
Gaining market and patient access in Europe has presented many cell and gene therapy companies with barriers. The advanced therapies industry is currently facing a dilemma: scientific advancement is exceeding market and reimbursement adaptation.
